Market research
300676.SHE BGI Genomics Co., Ltd
SHE CNY Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 16B
- P/E ratio
- Not available
- Analyst target
- 51.14
- Dividend yield
- Not available
- Beta
- 0.66
Profile
Instrument facts
- Exchange
- SHE
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- CNE100003449
- Market cap
- 16B
- P/E ratio
- Not available
- Analyst target
- 51.14
- Dividend yield
- Not available
- Beta
- 0.66
About
About BGI Genomics Co., Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and metagenomics and 16S/18S/ITS sequencing. It also provides RNA sequencing, long non-coding RNA sequencing, small RNA sequencing, iso-seq / pacbio transcriptome sequencing; single cell sequencing and high throughput single cell RNA-Seq; spatial transcriptome-stereo-seq; immune repertoire and pre-made library sequencing; and bioinformatics solutions. In addition, the company offers mass spectrometry, including proteomics, metabolomics, and multi-omics. Further, it provides clinical solutions for reproductive health, oncology, infectious disease, and chronic disease. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. The company was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd. operates as a subsidiary of BGI Group.
Research context
BGI Genomics Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 300676.SHE discussion.
5 years, 6 months ago
BGI Genomics Co., Ltd is currently in a long term downtrend where the price is trading 14.3% below its 200 day moving average.
From a valuation standpoint, the stock is 31.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.6.
BGI Genomics Co., Ltd's total revenue rose by 263.2% to $3B since the same quarter in the previous year.
Its net income has increased by 16742.3% to $1B since the same quarter in the previous year.
Finally, its free cash flow grew by 163.7% to $561M since the same quarter in the previous year.
Based on the above factors, BGI Genomics Co., Ltd gets an overall score of 4/5.